Immune Checkpoint Inhibitor Clinical Trial
Official title:
Induction Chemotherapy of Toripalimab With Docetaxel and Cisplatin Followed by De-escalation of Chemoradiotherapy Density in HPV-related Oropharyngeal Carcinoma in Chinese Populations
Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive. Several studies attempted to reduce the toxicities of treatments through reduced-dose radiation and showed promising results, but all data were collected from non-Chinese areas. Like nasopharyngeal carcinoma (NPC), oropharyngeal carcinoma may have different biological behavior and relationship with HPV infection. So the investigators studied whether toxicities reducing treatment with reduced radiation dose and omitted concurrent chemotherapy after good response to induction chemotherapy would maintain survival outcomes while improving tolerability for patients with HPV-positive oropharyngeal carcinoma. Immune checkpoint inhibitors (ICIs) have proved to improve outcomes of head and neck cancers including EBV-related NPC. Oropharyngeal carcinoma was considered to be similar with NPC in terms of immune environment. So we added anti-PD-1 antibody Toripalimab to induction chemotherapy in order to achieve better response rates to receive de-escalation chemoradiotherapy followed.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05848011 -
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT06197581 -
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
|
N/A | |
| Recruiting |
NCT05576961 -
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04659382 -
Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
|
Phase 2 | |
| Withdrawn |
NCT05653531 -
Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
|
N/A | |
| Completed |
NCT04470440 -
Thyroid Dysfunction and Nivolumab Reponse in NSCLC
|
||
| Recruiting |
NCT05554432 -
Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2
|
||
| Recruiting |
NCT05863260 -
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
|
||
| Recruiting |
NCT06259162 -
LAG3 Expression in Triple Negative Breast Cancer
|
N/A | |
| Not yet recruiting |
NCT05810402 -
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
|
N/A | |
| Recruiting |
NCT05385185 -
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05311566 -
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
|
Phase 2 | |
| Recruiting |
NCT06227728 -
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
|
||
| Recruiting |
NCT05799898 -
Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors
|
||
| Recruiting |
NCT04414969 -
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04891016 -
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04419441 -
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma
|
||
| Not yet recruiting |
NCT05915481 -
Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT05675111 -
Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)
|
||
| Recruiting |
NCT06007274 -
Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors
|